Kaloba

Pelargonium sidoides root extr (EPs 7630).

Each film-coated tablet and 100 g syrup contain 20 mg and 250 mg of EPs 7630, respectively, a proprietary extract of the dried roots of Pelargonium sidoides.

Pharmacology: FC Tablet: Unique Product: Kaloba tablet represents a unique product containing a proprietary extract of Pelargonium sidoides roots from South Africa.
Works Differently: Kaloba tablet is a new kind of natural health product. Unlike other products that only mask symptoms, Kaloba tablet has a multiple modes of action that supports the body's own defense mechanisms.
Provides Relief: Mild symptoms can stress the body's immune system and cause discomfort to the airways, often in a recurring cycle. Kaloba tablet supports the immune system.
Syrup: Modulation of specific/unspecific immune response and bacterial static properties are the primary properties of Kaloba.
Evident in published studies, Kaloba inhibits docking of viruses and bacteria to mucosa membranes, thus providing a protective effect. Immunomodulating properties activate specific/unspecific immune system eg, the macrophages to phagocytic pathogens. Exhibits moderate bacterial static activity on various gram-positive and gram-negative bacteria strains. Prevent proliferation of bacteria, thus preventing secondary bacterial superinfection. Increases ciliary beat frequency thereby improving transport of vicious phlegm and depriving the pathogens of a breeding ground for further multiplication.
Pharmacokinetics: Syrup: Kaloba is a complex mixture of multitude of components which are to be considered as a whole active substance. Pharmacokinetic data on the individual substances are not yet available.

May provide relief for discomfort associated with common cold and mild cough.

FC Tablet: Adults & children over 12 years: Take 1 tablet 3 times per day.
Children between 6-12 years: Take 1 tablet 2 times per day (morning & evening).
Syrup: Adults and children >12 years: 7.5-15 mL 3 times/day. Children 6-12 years: 5 mL 3 times/day. 1-5 years: 2.5 mL 3 times/day.
Duration of Treatment: After subsiding of the symptoms, it is recommended to continue the treatment for 2 more days in order to prevent a relapse.
Administration: May be taken with or without meals.

Kaloba should not be taken during pregnancy and lactation, as no adequate studies are available.
If the patient has severe liver diseases, as no sufficient experience is available in these fields.
If the patient is allergic to the active substance or to any of the excipients.

If the patient's condition does not improve within one week, in case of fever lasting for several days, liver dysfunction of different origin, shortness of breath or bloody sputum, please consult the doctor.

Kaloba should not be taken during pregnancy and lactation, as no adequate studies are available.

Gastrointestinal disorders: Uncommon: Gastrointestinal complaints.
Rare: Mild gingival bleeding.
Respiratory, thoracic and mediastinal disorders: Rare: Mild nasal bleeding.
Skin and subcutaneous tissue disorders/immune system disorders: Rare: Hypersensitivity reactions.
Hepatobiliary disorders: Liver dysfunction of different origin; the casual relationship between this finding and the application of the product has not been demonstrated. The frequency is not known.

Store at below 30°C and out of direct sunlight.

Other Drugs Acting on the Respiratory System

A13 - TONICS ; Used as tonics.

GSL